Spin-Out Step-Ups Reflect Bulk, Not Risk
This article was originally published in Start Up
Executive SummaryAn analysis of a group of Big Pharma and big biotech spin-outs, which tend to raise more private money than their build-from-scratch bretheren, shows that while these firms are certainly heftier--and often considered better equiped to succeed in the public markets--their pre-money step-ups are in the end, nothing special.
You may also be interested in...
Recent excitement around exosomes underscores their potential to solve drug delivery challenges that have limited the power and applicability of the biopharma industry’s growing arsenal of therapeutic modalities.